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ABSTRACT
We examined data and patterns in clinical islet transplant studies registered on ClinicalTrials.gov
(CTgov) for treatment of type 1 diabetes (T1D), with a goal of extracting insights to apply in the
design of a pluripotent stem cell-derived islet therapy. Clinical islet transplantation, as a cell ther-
apy (rather than solid organ transplant) is a unique precedent for stem cell-based islet therapies.
Registration activity shows that the ﬁeld is not growing signiﬁcantly, and newer registrations sug-
gest that the reasons for stagnation include need for a more optimal site of infusion/transplanta-
tion, and especially a need for better immune protective strategies to advance a more effective
and durable therapy for T1D. STEM CELLS TRANSLATIONAL MEDICINE 2019;8:209–214
SIGNIFICANCE STATEMENT
Clinical experience with islet transplantation is small, limited by donor availability and regulatory
approval in the U.S., but still provides an important precedent for companies developing stem
cell-based therapies for type 1 diabetes. This article reviews patterns in islet transplantation from
the ClinicalTrials.gov registry, emphasizing lessons that should be applied to new stem cell-based
therapies. In particular, immunogenicity of allogeneic islets is an important problem, and optimal
site for transplantation is still under investigation. Stem-cell derived islets have potential to treat a
broader range of patients with type 1 diabetes than can be treated with current clinical protocols.
INTRODUCTION
We used the search terms—“islet transplanta-
tion” and “type 1 diabetes” (T1D)—in reviewing
the ClinicalTrials.gov (CTgov) database. The data-
base is not curated, so there are likely overlap-
ping trials and trials that represent continuations
of earlier trials registered, and we did not con-
tact centers to clarify these issues. Finally, we
removed some studies for analysis in this
review, if studies never got off the ground or
had an “unknown” status after registration,
or were not clearly focused on T1D and out-
comes after islet transplantation. Islet auto-
transplantation studies are not part of this
review, but islet xeno-transplantation studies
are, because of their (immunologic) relevance
to allogeneic transplants. Islet allotransplants
are only performed in the U.S. at centers Food
and Drug Administration (FDA) approved to
study islet transplantation for patients with
T1D, and so they must register on CTgov. Con-
sequently, some of the single center registra-
tions are largely observational studies of local
practice and results (although listed as phase I/II),
rather than reporting interventional trials. Eighty
percent of the CTgov listings are for single-
center studies. Another important reason that
randomized control trials were not adopted for
allogeneic islet transplantation is the unwilling-
ness of patients to be assigned to a control
group [1]. Activity status of the clinical trial regis-
tries is shown in Table 1.
Although the FDA issued reporting require-
ments for studies registered on CTgov in
2016—at that time only 23,000 of the 224,000
studies registered had results posted [2]—our
review suggests that reporting is still a prob-
lem. Access to actual results was major issue in
reviewing the islet transplant experience on
the CTgov website. Less than 1/5 of the “com-
pleted” trials we reviewed had results, a total
of only 10 relevant studies. Part of the low
reporting rate may be a reﬂection of the small
number of islet transplants per center, which
also limits statistical analysis of the CTgov data-







School of Medicine, Los
Angeles, California, USA
Correspondence: Marie Csete,
M.D., Ph.D., Caltech Medical
Engineering (Moore Building),





Received July 17, 2018;
accepted for publication




This is an open access article
under the terms of the Creative
Commons Attribution-
NonCommercial-NoDerivs
License, which permits use and
distribution in any medium,
provided the original work is
properly cited, the use is non-
commercial and no modiﬁca-
tions or adaptations are made.
STEM CELLS TRANSLATIONAL MEDICINE 2019;8:209–214 www.StemCellsTM.com © 2018 The Authors
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
HUMAN CLINICAL ARTICLE
completed studies for which the Principal Investigator (PI) had
posted actual enrolment numbers, by searching PubMed, to
extend the amount of information extractable from CTgov.
In 2016, 215 solid organ pancreas transplants were per-
formed in the U.S., down from 1,500 performed in 2004 [3].
We did not include pancreas transplants in this analysis.
The Collaborative Islet Transplant Registry (citregistry.org) sup-
ported by the NIH is also an important and extensive source of
information approximately islet transplantation, and its most
recent annual report (covering transplants done through 2013)
was consulted for this review [4]. Nonetheless, the CTgov data-
base is the most up-to-date resource for examining trends in
islet transplantation worldwide. CTgov also provides a unique
history arc of clinical efforts in islet transplantation, including
reasons for termination of studies, as well as studies registered
after the latest Collaborative Islet Transplant Registry (CITR)
report. Here, we review the database for patterns of activity
that indicate factors in islet transplantation that need optimiza-
tion, common and distinctive features of inclusion and exclusion
criteria, and lessons from failed studies that can inform design
of stem cell-based islet transplantation clinical trials. Although
the registry changes frequently, a review of past studies is a
solid foundation to further build upon.
BRIEF HISTORY OF ISLET TRANSPLANTATION (CONTEXT FOR THIS
ANALYSIS)
In 1977, the NIH convened a conference to review the poten-
tial for clinical islet transplantation [5] for treatment of T1D,
resulting in a summary conclusion that clinical islet transplan-
tation was biologically feasible. Islet transplantation was per-
formed in a few centers for the decades following, but the
modern islet transplant era really began with the publication
of the Edmonton protocol [6], in which the major innovation
was use of an immunosuppressive regimen without corticoste-
roids. An international study of 36 patients transplanted using
the Edmonton protocol followed the initial report: in this
study a cumulative islet “dose” of at least 10,000 islets/kg was
delivered with ≥2 islet infusions into the portal vein, unless
insulin independence was achieved by one infusion [7].
Canada declared islet transplantation a standard clinical (non-
experimental) procedure in 2001, allowing government reim-
bursement for the procedure. Subsequently the U.K., Sweden,
Switzerland, France, and Italy followed suit [8].
Although the Edmonton protocol led to improved clinical
outcomes over early historic experience, sustained insulin
independence is not guaranteed after islet transplantation
(NCT00434811). A review of 347 allogeneic islet transplant
recipients from the Collaborative Islet Transplant Registry,
published in 2012 showed that 59% of islet recipients were free
of severe hypoglycemic events and had HbA1c levels <6.5% at
1 year post-transplant (a composite end-point). Of these, 69%
at 2 years, 54% at 3 years and 44% at 4 years sustained the pos-
itive end-point outcome [1]. A subsequent phase III CITR study
conﬁrmed effectiveness of islet transplantation in reducing
severe hypoglycemic events in most recipients, with highly sig-
niﬁcant improvement in Clarke [9] and HYPO [10] scores.
Median HbA1c levels decreased from 7.2% to 5.6% in the trans-
plant cohort of 48 subjects from 8 academic centers [11]. The
most recent CITR study shows that insulin-independence is
achieved in just over 40% of islet recipients at 1 year but falls
to half that at 5 years [4]. Nonetheless, freedom from severe
hypoglycemic events is an important clinical goal that can be
achieved without complete insulin independence. It is important
to note the small number of patients in these important multi-
center reports, as small numbers are a problem with analyzing
the CTgov registry critically, reﬂecting a reality of the ﬁeld.
RESULTS AND DISCUSSION
General Patterns
More than 140 clinical studies, either inactive (completed, with-
drawn, terminated, or other/unknown status) or currently active
(not yet recruiting, recruiting, enrolling by invitation, and active
but not recruiting) were included in this analysis. The year of
CTgov registration reﬂects the history of clinical islet transplan-
tation. The very ﬁrst trials were based at NIH and explored
recipient eligibility. A peak of activity surrounds publication of
the Edmonton protocol, and new trial registrations did not pick
up after that time (2006–2008). However, the nature of the tri-
als registered from 2011 to 2018 shifted toward exploration of
novel implant sites (gastric submucosa, intrabone marrow, sub-
cutaneous, anterior chamber of the eye for diabetic retinopathy,
and omentum) and approaches to reducing graft rejection with
new devices (physical barriers) or immune modulators (chemical
barriers). The initial year of registration is shown in Figure 1.
Table 1. Activity status of islet transplantation CTgov registrations
(June 2018)
Status Number of studies
Not yet recruiting (new) 3
Recruiting 26
Active, not recruiting 12
Enrolling by invitation 2
No longer available 3
Completed 47
Completed, has results 11 (Note: 10 relevant)
Withdrawn 9
Terminated 11
Terminated, has results 4
Unknown 13
Figure 1. Number of new registrations for islet transplantation
clinical trials for type 1 diabetes (y axis) for each year (x axis). Data
were obtained by the “Date ﬁrst posted” notation for each trial.
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Islet transplantation is international, but the number
of active centers is very small: in the CTgov registry, 26
U.S. centers, 4 Canadian, 28 European, and 2 Asian centers are
represented. By comparison, in the U.S., the United Network for
Organ Sharing lists 256 centers with some transplant programs,
so only approximately 10% of U.S. transplant centers offer islet
transplantation. Another way of looking at these numbers: only
1.5% of transplantation studies registered in the CTgov data-
base are islet studies (141 out of 10,921). Of the U.S. centers in
the database, at least two are no longer active. When viewed in
the light of the small numbers of patients transplanted per cen-
ter, these numbers represent a challenge for enrolling sufﬁcient
numbers of patients in clinical trials, and as noted below, poor
or no enrolment is a common reason for clinical studies to be
withdrawn. Furthermore, the site numbers suggest that ﬁnding
centers with deep expertise in islet transplantation to host new
stem cell based trials is not straightforward.
Outcomes in Completed Studies with Posted Results
Only 10 relevant completed studies were found with posted
results (20% of completed studies). The total actual enrolment in
these 10 studies was 86 but only 74 patients completed study.
Overall, serious adverse events (SAE) were reported in 66% of
patients. Of SAE that could be related to the immunosuppressive
drug regimen, leukopenia was reported in 20 of 86 subjects and
infection in 13. We looked at outcome and SAE data at 1 year
whenever possible, but the data are not straightforward to pull
from the records since each center had different primary and
secondary endpoints; there was not a single primary or second-
ary end-point in common posted by all these centers. For primary
outcomes, the primary composite endpoint of normal range
HbA1c level (e.g., HbA1c ≤ 6.5%) and elimination of hypoglycemia
recommended by FDA [12] was not reported by most centers.
The HbA1c goal of ≤6.5% reported as a secondary end-point in
4 studies was reached by 23 of 30 subjects. The most commonly
reported primary end-point was insulin-independence and at
1 year; 30 of 65 subjects met that end-point. Secondary end-
points of hypoglycemia incidence were reported in various ways:
percent subjects with NO hypoglycemic episodes was reported
(by two centers); reduced number of hypoglycemic episodes,
increased awareness of hypoglycemic episodes, or numbers of
episodes per month were also ways of reporting; 23 of 30 sub-
jects met one of these criteria at 1 year post-transplant.
Learning from (Failure) Experience
We examined the 11 “Terminated” studies to determine reasons
for premature closure of the trials. The primary reason given for
termination was lack of enrolment in three studies. No reason
was given for 3 studies, including one single-center study that
had an actual enrolment of 30 subjects; another closed because
the PI left the university, and another due to “feasibility” issues.
The closure of three studies points to the difﬁculty in achieving
immune tolerance of allograft islets: one study (NCT00315614)
in which donor CD34+ cells were given to three subjects was
closed because tolerance was not achieved, and pharmacologic
immunosuppression could not be withdrawn. Similarly, a B lym-
phocyte immunotherapy approach using the anti-CD20 monoclo-
nal antibody, rituximab, closed after two subjects were studied,
for lack of efﬁcacy. For “withdrawn” studies, the major reason
for withdrawing the study was lack of enrollment or in one case,
“university decision.”
Inclusion/Exclusion Criteria
In order to compare results for stem cell based therapies to islet
transplantation, inclusion and exclusion criteria (i.e., the patient
phenotype) should be similar to those developed over time for
islet transplantation. A general philosophy ruling eligibility of
T1D patients for islet transplantation, because of the well-
known risks of life-long immunosuppression, is that T1D must
not be controllable using optimal intensive medical manage-
ment. The vast majority of clinical trials require patients to have
been diagnosed with T1D for at least 5 years, except the
unusual trials examining islet transplantation speciﬁcally for
newly diagnosed patients (NCT002505893 and NCT00807651).
More than half the trials also specify that disease onset must
have been before age 40 years. Age is usually speciﬁed between
18 and 65 years; patients aged 35 years and younger are less
likely to achieve insulin-independence or reduction of daily insu-
lin requirement than older patients [4]. All programs require
that patients are experiencing symptomatic hypoglycemic epi-
sodes and/or unrecognized hypoglycemic episodes despite opti-
mal intensive medical management. Most centers also require
lack of c-peptide production to conﬁrm no residual islet func-
tion (with slight differences in how c-peptide is assessed) and
an abnormal HbA1c despite medical management. In the CTgov
registry the HbA1c upper thresholds do vary considerably from
center to center with a range of 7%–12%.
Cardiovascular disease is a common complication of T1D,
so cardiac risk factors and cardiac functional status are often
speciﬁed in exclusion criteria, with some variability between
centers. For example, the upper limit of normal body mass
index (BMI) speciﬁed ranges between 26 and 35 kg/m2 with a
mean overall of 28.7 kg/m2 (and European study mean of
29 kg/m2). All three Chinese studies specify an upper BMI limit
of 27 kg/m2. A maximum BMI criterion excludes patients who
would require a larger mass of islets for transplant and poten-
tially a more complicated procedure, and may help to exclude
patients with insulin-resistance. Several centers specify that
eligible subjects must weigh at least 50 kg, possibly to ensure
an adequate size of the portal vein.
Renal disease is also a common complication of T1D. Cen-
ters that perform islet transplantation may also perform simul-
taneous islet and kidney transplants, or islet transplants after
kidney transplant. All studies exclude subjects with signiﬁcant
proteinuria (macroalbuminuria). Serum creatinine exclusion
criteria cutoffs (above 1.5–1.6 mg/dl) are usually used in asso-
ciation with renal functional testing. Although glomerular ﬁl-
tration rate (GFR) is generally considered a better overall
measure of renal function than creatinine clearance (CrCl), cre-
atinine clearance criteria of renal function are used in approxi-
mately 1/3 of the clinical trial listings. Creatinine clearance
tends to overestimate renal function compared with GFR [13],
both measures tend to decline with age; we did not separate
out CrCl or GFR criteria according to the precise methods used
or otherwise try to normalize the reported renal function
exclusion criteria. When CrCl is used to deﬁne kidney function
inclusion criteria, the lowest acceptable value ranges from
50 to 80 ml/minute with a mean of 64.2 and median of
60 ml/minute. When GFR is used for inclusion criteria the lowest
function for inclusion ranges from 40 (corresponding to moder-
ate chronic kidney disease [CKD]) to 80 ml/minute (mild CKD),
with an arithmetic mean of 67 and median of 70 ml/minute.
The vast majority of programs therefore do not accept patients
www.StemCellsTM.com © 2018 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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for islet transplantation when severity of kidney function has
progressed to moderate (stage III) disease. This criteria is
unlikely to change given the results of the latest international
trial [11] in which GFR continued to decline in the year after islet
transplantation despite 87.5% of subjects meeting the compos-
ite primary end-point indicating good glycemic control. Addi-
tionally, immunosuppressive regimens, especially calcineurin
inhibitors, may also contribute to further renal functional
decline [14].
Marrow function is also evaluated for several reasons. First,
immunosuppressive regimens are generally marrow suppressive.
Second, bleeding complications of the surgical procedure are not
uncommon. Platelet counts are routinely screened; ﬁve of
48 subjects had a serious bleeding adverse event in the recent
international trial [11]. Most often a platelet count above
100,000 per mm3 is required, with some centers setting less
stringent (80,000 per mm3) and a few more stringent (150,000
per mm3) criteria. The hemoglobin criteria are surprisingly wide,
with some centers accepting anemic patients (minimal hemoglo-
bin, Hgb of 7 g/dl) and others accepting only (male) patients with
Hgb > 13 g/dl. Hemoglobin for women and men are usually spec-
iﬁed, with a lower number for women acceptable. The criteria
for white blood cell counts are more uniform with most pro-
grams requiring a total white cell count of at least 3,000 per μl.
As in other clinical transplant programs, patients with
active systemic infection or malignancy (except basal or squa-
mous skin cancer) are excluded; signiﬁcant end-organ liver dis-
ease, neurologic or psychiatric disease are exclusion criteria.
Particular to T1D, patients with untreated proliferative diabetic
retinopathy are also excluded.
Immunosuppression
The main concern with islet transplantation, beyond safety, con-
tinues to be long-term survival of the graft. In spite of signiﬁcant
advancements in transplant immunosuppressive regimens and
improved islet survival, current immunosuppression drug combi-
nations have failed to signiﬁcantly improve single-donor graft
success rates: the majority of patients still require two or more
islet transplants (two or more donors) to achieve clinically signiﬁ-
cant improvement in disease. For this reason, the majority of the
trials (64%, or 91 studies out of 141) recorded in CTgov, including
currently active trials, continue to investigate the efﬁcacy on islet
survival of different combinations of induction (i.e., administered
prophylactically at the time of transplant) and maintenance
immune suppressive agents (i.e., post-transplant long-term regi-
men). Multidrug approaches involving agents with different
mechanisms of action are typically being assessed in these stud-
ies to both reduce toxicities and improve outcomes. In addition
to pharmacologic immunosuppressive regimen, several trials are
currently exploring the use of regulatory T cells (Tregs) to induce
immune tolerance by curbing the host autoimmunity and alloim-
munity (NCT03444064 and NCT03162237). Tregs not only inhibit
effector T cells, but regulate other lymphocytes and antigen
presenting cells to turn down the immune response [15]. Other
centers are investigating immunomodulatory strategies that
transiently deplete B lymphocytes to promote islet transplant
engraftment and ultimately promote insulin independence
(NCT00468442, NCT01049633, and NCT00434850). This approach,
which demonstrated promising preclinical results [16, 17] has not
yet been successful in small numbers of subjects and will require
further optimization.
We also looked at the 10 relevant completed studies with
posted results to determine the range of immunosuppressive reg-
imens used. Four of the studies used the Edmonton protocol regi-
men (induction with daclizumab, maintenance with sirolimus +
tacrolimus) and the rest were testing or using other regimens.
Optimization of the Implant Site
Islet transplantations are actually islet infusions into the portal
vein, delivering islets to the liver. The liver has a unique two-
input blood supply via the portal vein and hepatic artery, with
the portal vein draining the entire gastrointestinal tract and the
hepatic artery supplying oxygen to the liver. Advantages of portal
vein include its size with sufﬁcient diameter for the islet infusion,
and its accessibility for percutaneous cannulation and pressure
monitoring. The portal venous blood also contains a rich trophic
factor supply of gut hormones. Nonetheless, the liver is not an
ideal environment for islet engraftment and survival. Unlike
orthotopic solid organ transplants or hematopoietic stem cell
transplants that are placed in or home to their normal environ-
ment, transplanted islets are expected to thrive in an alien envi-
ronment. Upon infusion, the islets become trapped in an
uncontrolled manner in the hepatic microvasculature and islets
within such plugs must survive a period of relative hypoxia.
These islets must actively migrate across the endothelial lining
and subsequently establish residency within the hepatic paren-
chyma. It is estimated that less than half of transplanted islets
survive the ﬁrst 48 hours following infusion into portal vein [18].
Clinical Trial Design for Alternative Islet Sources and
Reduced Pharmacologic Immune Suppression
Alternative sources of cadaveric donor islets in development
are islets generated in the laboratory from human pluripotent
stem cells (PSCs) including induced PSCs [19], human exocrine
progenitor cells [20] and islets from neonatal piglet pancreata.
The safety and efﬁcacy of PSCs-derived islets (NCT03162926,
NCT02239354, NCT03163511, and NCT02939118) and porcine
islets (NCT01736228, NCT03162237, and NCT01739829) are
currently subjects of clinical trials. Alternatives to systemic immune
suppression under study are encapsulation devices that provide a
physical barrier between the graft and the host immune system
(NCT02064309, NCT00940173, NCT01739829, and NCT01736228)
as well as new pharmacologic and biologic approaches to induce
transplant tolerance (NCT03444064, NCT03162237, NCT00468442,
NCT01049633, and NCT00434850).
The factor that most dramatically inﬂuences clinical trial
design and practice is elimination of long-term systemic immune
suppression. Removal of these agents could potentially enable
enrolment of patients with (more signiﬁcant) renal dysfunction,
for example. In this case, a relevant clinical endpoint would be
the observation of islet transplant on renal function in the
absence of immune suppression to determine if the stabilization
of diabetes (without potentially confounding nephrotoxic drugs)
can also stabilize renal function. Removal of immune suppres-
sion from the clinical trial protocol also lowers the long-term risk
to patients, potentially extending the eligible pool of patients to
those with less severe forms of diabetes, provided the risk/bene-
ﬁt ratio of encapsulated islets proves low.
Advancing the Field
Islet transplantation remains challenging with enormous
resources mobilized to yield positive results that do not “cure”
© 2018 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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disease and are associated with signiﬁcant risk and side-
effects. With maturation of stem cell biology and tissue engi-
neering, we are optimistic that a safe and effective PSCs-based
therapy will be developed along with engineered immune bar-
riers that obviate need for pharmacologic immunosuppression.
Figure 2 summarizes our conclusions approximately how the
treatment of T1D can be improved beyond the use of cadav-
eric islet grafts with a stem cell-based strategy.
CONCLUSION
An examination of the CTgov registrations for islet transplantation
highlights current bottlenecks to broader use of islet transplanta-
tion for treatment of T1D. These bottlenecks include poor islet
survival and signiﬁcant side-effects, many associated with obligate
pharmacologic immunosuppression. Current inclusion criteria
emphasize the most severe forms of T1D because the risk of life-
long pharmacologic immunosuppression is high and because the
therapy does not reliably result in insulin-independence. The most
striking improvement in outcomes of islet transplantation came
with adaptation of the Edmonton protocol, further highlighting
the importance of ﬁnding an optimal and safe method to avoid
immune destruction of islet grafts. Newer CTgov registrations
emphasize novel approaches to promoting islet survival: T
regulatory cells to promote graft tolerance, physical barriers to
immune cell graft invasion, stem cell sources of islets, and extra-
hepatic sites for engraftment. Because of the small numbers of
islet transplantations performed and regulatory hurdles inherent
in ﬁrst-in-human trials, these promising therapies will take time to
evaluate, but all represent potential major improvements toward
more optimal use of islets for treatment of T1D.
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